Efficacy of administration of weekly docetaxel combined with platinum as a first-line treatment for patients with advanced non-small cell lung cancer.
- Author:
So Yeon KIM
1
;
Hun Mo RYOO
;
Sung Hwa BAE
;
Hyun Young JUNG
;
Kyung Chan KIM
;
Dae Sung HYUN
;
Sang Chae LEE
;
Kyeong Ok KIM
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Young Lan KWEON
;
Ga Young KIM
;
Gyu Young KIM
;
Chi Young JUNG
;
Yeon Jae KIM
;
Byeung Gi LEE
;
Jung Lim LEE
;
Won Sik LEE
Author Information
1. Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, Korea.
- Publication Type:Original Article
- Keywords:
Weekly dosing;
Dcisplatin;
Carboplatin;
Non-small cell lung Cancer
- MeSH:
Carboplatin;
Carcinoma, Non-Small-Cell Lung*;
Cisplatin;
Fever;
Humans;
Infusions, Intravenous;
Neutropenia;
Platinum*;
Survival Rate
- From:Korean Journal of Medicine
2007;72(6):625-631
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUDN: Docetaxel is a highly effective chemotherapeutic agent with proven efficacy for non-small cell lung cancer (NSCLC). However, myelosuppression can be a substantial concern when docetaxel is administered every 3 weeks. Weekly administration of low-dose docetaxel has demonstrated a comparable efficacy together with a distinct toxicity profile with reduced myelosuppression. We conducted a phase II study of weekly administration of docetaxel and cisplatin or carboplatin in patients with advanced NSCLC to evaluate efficacy and safety. METHODS: Twenty-nine patients with advanced or metastatic NSCLC who had not received prior treatment were enrolled in the study. The patients received intravenous infusions of docetaxel (35 mg/m2 on days 1, 8, 15) and cisplatin (75 mg/m2 on day 1) or carboplatin (AUC 6), followed by a week of rest. RESULTS: Twenty-six patients were assessable for efficacy and all patients were assessable for toxicity determination. The overall response rate of the regimen was 44.8%. The median survival was 11.3 months, and the 1-year survival rate was 37%. Of the hematologic toxicities, grade 3/4 neutropenia were observed in 12.6% of the patients, but there were no episodes of neutropenic fever. Non-hematologic toxicities were mild. CONCLUSIONS: With this weekly dosing regimen, although efficacy is comparable, myelosuppression is substantially less, and the overall tolerability profile is better than with dosing every 3 weeks.
